Depression is common, costly, debilitating, and associated with increased risk of suicide. It is
one of the leading global public health problems. Although existing available …

Background Psychedelic therapy shows promise for Major Depressive Disorder, especially
when treatment-resistant, as well as life-threatening illness distress. The objective of this …

Treatment‐resistant depression (TRD) is common and associated with multiple serious
public health implications. A consensus definition of TRD with demonstrated predictive utility …

Importance Psilocybin shows promise as a treatment for major depressive disorder (MDD).
Objective To evaluate the magnitude, timing, and durability of antidepressant effects and …

A single dose of psilocybin, a psychedelic that acutely causes distortions of space–time
perception and ego dissolution, produces rapid and persistent therapeutic effects in human …

Background Psilocybin has been suggested as a novel, rapid-acting treatment for
depression. Two consecutive doses have been shown to markedly decrease symptom …

Psychedelics have attracted medical interest, but their effects on human brain function are
incompletely understood. In a comprehensive, within-subjects, placebo-controlled design …

Design Open-label Randomized Randomized, double-blind, placebo-controlled
Randomized, double-blind, placebo-controlled Randomized, double-blind, placebo …

Psilocybin is being investigated as a treatment in adults with treatment-resistant depression
(TRD). Withdrawal from serotonergic antidepressant drugs is a common prerequisite for …

Psychedelics make up a group of psychoactive compounds that induce hallucinogenic
effects by activating the serotonin 2A receptor (5-HT2AR). Clinical trials have demonstrated …